Marcel van den Brink, MD, PhD Medical Oncologist, Head of the Division of Hematologic Oncology and the Alan N. Houghton Chair Biography Physician-scientist Marcel R. M. van den Brink studies the immunology of bone marrow transplantation. His expertise is in allogeneic (donor-provided) blood stem cell transplantation for adult cancer patients. Allogeneic hematopoietic stem cell transplantation (HSCT) is a therapy for a variety of malignancies, including leukemias, lymphomas and myeloma. Several complications limit its use including relapse of malignancy, graft versus host disease, and prolonged immune depletion caused by the conditioning required for successful transplantation – all of which can lead to increased morbidity and mortality after allo-HSCT. His laboratory uses murine HSCT models to study clinically important problems in HSCT and to test novel therapeutic strategies which can be translated into clinical practice. Van den Brink’s major projects include strategies to enhance post-transplant immune reconstitution, the role of T cells in graft-versus-host-disease and graft-versus-tumor activity. Education & Training Universiteit Leiden, South Holland, MD, PhD Duke University Medical Center, Durham, NC, Residency Beth Israel Deaconess Medical Center, Boston, MA, Fellowship Awards & Honors 2013: The Association of American Physicians, elected member 2004: American Society for Clinical Investigation, elected member 2000: Damon Runyon Scholar Award of the Cancer Research Fund; V Foundation for Cancer Research Scholarship 1999: Amy Strelzer Manasevit Scholar Award of the National Marrow Donor Program 1996: Physician Scientist Award of the Howard Hughes Medical Institute